Ustekinumab: a novel therapeutic option in Crohn's disease. (2nd August 2016)

• Record Type: Journal Article
• Authors: Simon, E. G.; Samuel, S.; Ghosh, S.; Moran, G. W.
• Is Part Of: Expert opinion on biological therapy. Volume 16:Number 8(2016:Aug.)
• Page Start: 1065
• Page End: 1074
• Publication Date: 2016-08-02
• Subjects: Anti-TNF agents -- biologic therapy -- Crohn's disease -- ustekinumab; Gene therapy -- Periodicals; Protein drugs -- Periodicals; Peptide drugs -- Periodicals; Immunotherapy -- Periodicals; Drug delivery systems -- Periodicals; 615.5
• DOI: 10.1080/14712598.2016.1205582
• Languages: English
• ISSNs: 1471-2598

Abstract

ABSTRACT: Introduction : Although anti-tumour necrosis factor (TNF) agents have caused a paradigm shift in the management of moderate-to-severe Crohn's, they are sometimes associated with diminished or absent response in a considerable proportion of patients. Hence agents targeting pathways other than TNF are needed. Ustekinumab is a monoclonal antibody directed against the p40 subunit of IL-12 and 23. Areas covered : This manuscript summarises the available evidence on the efficacy and safety of Ustekinumab in Crohn's disease through data available from randomised controlled trials and compassionate use programs across the world. Expert opinion : Current literature strongly supports the fact that ustekinumab is clinically efficacious and reasonably safe for induction and maintenance of remission in moderate-to-severe Crohn's disease.